Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MCV4 in 7-17 Year Olds
NCT06700148Phase 3Completed
- Sponsor
- CanSino Biologics Inc.
- Start
- Dec 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Meningococcal conjugate vaccine quadrivalent in meningococcal meningitis, sponsored by CanSino Biologics Inc.. Started Dec 2024; status: completed.
02
Drugs
Meningococcal conjugate vaccine quadrivalent
03
Conditions
meningococcal meningitis
Beyond the preview
Go deeper on NCT06700148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06700148.